March 2, 2017
(STAT News) – Proove has grown rapidly by tapping into the public angst over surging opioid addiction. It is one of many companies touting personalized DNA-based tests backed by little or no credible scientific data showing their reliability. That’s because a regulatory loophole has left huge swaths of the multibillion-dollar genetic testing industry largely free of government oversight. A STAT investigation found that Proove employees stationed in physicians’ offices pushed unnecessary tests on patients — a practice called “coercion” by one former manager — and they sometimes completed research evaluation forms on behalf of doctors, rating the tests as highly effective when they weren’t. In fact, Proove tests of DNA captured by swabbing inside a patient’s cheek were so unreliable that many physicians disregarded the results. There was scant evidence, said the company’s former chief scientist, that the tests improved patient outcomes.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.